Cedars-Sinai Launches Venture Fund in the Netherlands
With Coronet Ventures Netherlands, Cedars-Sinai Establishes Its Third International Venture Fund
Cedars-Sinai Technology Ventures has launched Coronet Ventures Netherlands, a new venture fund that will invest in health and life sciences startups in the Netherlands.
The new fund is Cedars-Sinai’s third international venture initiative, deepening the organization’s commitment to investing in novel healthcare technologies worldwide to enhance patient care. Cedars-Sinai leaders made the announcement in June at healthcare innovation conference HLTH Europe 2025.
“At Cedars-Sinai, we are dedicated to advancing innovations that improve patient care while making healthcare more efficient and cost effective. With Coronet Netherlands, we are building new global partnerships to access leading science, accelerate clinical translation and help bring breakthrough technologies to patients faster,” said James D. Laur, JD, chief executive of Intellectual Property and Health Ventures at Cedars-Sinai, and co-founder of the Cedars-Sinai Accelerator.
Coronet Ventures Netherlands will focus on early-stage health technology and biomedical startups working on innovations targeted for the U.S. market, investing $50 million over the next decade. Through its relationship with Cedars-Sinai, the fund will be able to connect startups with vast clinical data to test and verify new technology, launch pilot programs and test products. Cedars-Sinai will likewise benefit from the innovations developed by the Dutch startups.
The fund is part of Cedars-Sinai Technology Ventures, which accelerates the translation of research and early-stage innovations into real-world healthcare by connecting scientists, entrepreneurs and investors with the U.S. market—ultimately driving advancements that will benefit patients at Cedars-Sinai and around the world. It previously established two other international investment funds—Coronet Ventures and Coronet Ventures Singapore. Building partnerships is key to its mission.
“This partnership allows us to create a platform with underlying capital that also offers deep clinical validation and commercialization support to help healthcare and biotechnology companies scale more quickly into the U.S.,” said Nirdesh K. Gupta, PhD, managing partner of Cedars-Sinai Intellectual Property Company.
The new venture fund builds on four years of collaboration between Cedars-Sinai Technology Ventures and Dutch innovators. Since 2021, Cedars-Sinai Technology Ventures has met with startups from the Netherlands to explore opportunities with the Cedars-Sinai Accelerator—a Technology Ventures subsidiary that supports early-stage companies with mentorship and a $100,000 investment.
Two Dutch startups have already participated in the accelerator program: HealthPlus.ai, which uses electronic health records and artificial intelligence to predict patients’ infection risk and assist with early medical intervention, and Syntho, which uses artificial intelligence to generate synthetic healthcare data used by medical researchers. Syntho has since completed a pilot program with Cedars-Sinai and is in discussions to collaborate with the organization’s Artificial Intelligence Lab.
Read more on the Cedars-Sinai Blog: A Technology Transfer Office Success